Test Price
550 AEDโ Home Collection Available
OLIG2 Immunohistochemistry Test โ Advanced Glial Tumor Subclassification
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited immunohistochemistry processing (Cert: INT/EGQ/2509DA/3139).
- Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for archival FFPE blocks or fresh biopsies; temperature-controlled chain-of-custody across Dubai, Sharjah, and Abu Dhabi.
- Clinical Guidance: Complimentary telephonic post-test result interpretation by a DHA-licensed specialist radiologist with integrated histopathology review.
- Direct Billing: Insurance verification and direct billing coordination via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The OLIG2 immunohistochemistry test specifically detects the oligodendrocyte transcription factor 2 protein within tumor tissue sections. This marker is essential for differentiating oligodendrogliomas from astrocytic neoplasms and other glial tumors, directly guiding surgical planning, chemotherapy selection, and prognostic stratification in neuro-oncology.
| Feature | DNA Labs UAE OLIG2 IHC Test | Standard Alternative |
|---|---|---|
| Methodology | Automated IHC using validated OLIG2 monoclonal antibody with digital image analysis and quantitative H-score | Manual IHC with semi-quantitative subjective scoring |
| Turnaround Time | 5 โ 7 business days from specimen receipt; expedited processing available | 7 โ 14 business days average |
| Clinical Integration | Whole-slide imaging, integrated histopathology report with IDH1/2 and 1p/19q reflex analysis | Standalone IHC report; no molecular contextualization |
| UAE Regulatory Adherence | Full compliance with UAE PDPL, Federal Law No. 2 of 2019, and DHA diagnostic standards | Variable compliance; may lack local health data protection integration |
Physician Insight & Safety Protocols
โThe OLIG2 transcription factor is a critical first-line marker for distinguishing oligodendroglial tumors from astrocytic neoplasms. Definitive classification, however, requires integrated interpretation with IDH mutation status and 1p/19q codeletion analysis. Patients must not modify treatment plans based on OLIG2 results alone; a complete neuro-oncological evaluation remains essential for safe therapeutic decision-making.โ โ Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory Precautions for Patients and Referring Physicians
โ ๏ธ Critical Clinical Guidance
- Do not discontinue, adjust, or initiate any oncological therapy solely on the basis of an OLIG2 IHC result without a comprehensive histopathological and molecular workup.
- Patients currently on anticoagulation or with known bleeding diatheses must coordinate with their neurosurgeon before any repeat tissue biopsy procedure.
- This assay is validated exclusively for tissue-based analysis; it is not indicated for cerebrospinal fluid, blood, or other liquid biopsy specimens.
Exclusion Criteria & Emergency Red Flags
- Not suitable for patients lacking a diagnostic tissue block (FFPE), biopsy slide, or histological specimen from the primary tumor site.
- Cannot be performed on cytology preparations, cell blocks, or fine-needle aspirates without formal histopathological correlation.
- Emergency Red Flags: If you experience acute neurological deterioration โ including sudden severe headache, unexplained vision loss, new-onset seizures, or focal weakness โ seek immediate emergency medical attention. Do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the OLIG2 IHC test and why is it ordered?
This immunohistochemistry assay detects the OLIG2 protein in tumor tissue, providing a critical diagnostic marker for oligodendrogliomas and other glial neoplasms. It is ordered when MRI or histopathology suggests a glial tumor of uncertain lineage, helping neuropathologists achieve precise classification and guide targeted therapy decisions.
2. How is the specimen collected and what are the logistics?
The test requires a formalin-fixed paraffin-embedded (FFPE) tissue block or a fresh biopsy specimen placed in 10% neutral-buffered formalin. Our Secure Medical Courier Solid Tissue Specimen Retrieval service provides temperature-controlled pickup within 2 hours across Dubai, Sharjah, and Abu Dhabi. Hospital extraction is strictly required; mobile home phlebotomy is not applicable for this tissue-based assay.
3. When will I receive my results and how are they interpreted?
Results are delivered within 5 to 7 business days from specimen receipt. A positive result indicates strong nuclear OLIG2 expression, consistent with oligodendroglial differentiation; negative staining points toward alternative diagnoses such as astrocytoma or glioblastoma. Every report includes a complimentary telephonic consultation with our specialist radiologist to guide next diagnostic or therapeutic steps.
4. What is the price and does insurance cover this test?
The total fee for the OLIG2 IHC test is 550 AED, inclusive of technical processing, digital slide analysis, and clinical interpretation. We offer direct insurance billing โ send your policy details via WhatsApp to +971 54 548 8731 for pre-verification before sample submission.
UAE Regulatory & Data Privacy Adherence
- Data Protection: All patient health information is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Governance: Our digital infrastructure conforms to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure storage, transmission, and audit logging of all diagnostic records.
- Clinical Safety & Consent: Specimen collection, handling, and diagnostic reporting adhere to the standards set by Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing patient consent protocols and clinical accountability.
- Accreditation: ISO 9001:2015 certified laboratory (Cert: INT/EGQ/2509DA/3139) with full DHA licensing under Facility License Number 1143.
Clinical & Logistical Metadata
| Test Name | OLIG2 Immunohistochemistry (IHC) Test |
| Price (AED) | 550 AED |
| Turnaround Time | 5 โ 7 business days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block or Fresh Biopsy in 10% formal-saline |
| Methodology Used | Automated Immunohistochemistry (IHC) with validated OLIG2 monoclonal antibody, digital whole-slide imaging, and H-score quantitation |
| ICD-10-CM Code | C71.9 โ Malignant neoplasm of brain, unspecified |
| LOINC Code | 21952-8 โ Microscopic observation [Identifier] in Tissue by Immunohistochemistry |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians